Immunocore

7 days ago · zacks.com

IMCR achieves target enrollment in the phase III TEBE-AM study investigating Kimmtrak in previously treated patients with advanced melanoma.

8 days ago · seekingalpha.com

Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

8 days ago · globenewswire.com

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK ® (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as early as end of 2026 (OXFORDSHIRE, England & CONSHOHOCKEN, PA & ROCKVILLE, MD, US, 14 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced the achievement of target patient enrollment (540 patients) in the TEBE-AM clinical trial (NCT05549297). TEBE-AM is a global, randomized, registrational Phase 3 clinical trial evaluating KIMMTRAK (tebentafusp) as monotherapy and in combination with pembrolizumab, versus Investigator's Choice, for the treatment of HLA-A*02:01-positive patients with advanced melanoma whose disease has progressed following prior therapy.

21 days ago · globenewswire.com

Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 1 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in September. Cantor Global Healthcare Conference 2026 Fireside Chat: Thursday, September 10, 2026, at 2:45 p.m.

28 days ago · zacks.com

Strong demand for Kimmtrak is fueling Immunocore's growth, while potential label expansion and late-2026 data could add further upside.

1 month ago · zacks.com

Immunocore's 3-month gain reflects Kimmtrak growth and pipeline progress, but valuation and mixed signals temper the momentum case.

1 month ago · zacks.com

Immunocore's Kimmtrak growth and late-stage catalysts strengthen its case, but a premium valuation and single-product risk raise the stakes.

1 month ago · zacks.com

Immunocore's Q2 revenue beat reflects strong Kimmtrak demand, but an EPS miss and distributor stocking headwind cloud the near-term outlook.

2 months ago · zacks.com

IMCR incurs wider-than-expected Q2 loss. However, revenues beat as sole drug Kimmtrak sales rise 18.3% year over year on higher U.S. and international sales.

2 months ago · zacks.com

The average of price targets set by Wall Street analysts indicates a potential upside of 77.9% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.